Laura Amaducci

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

PierFranco Conte, Antonio Frassoldati, Giancarlo Bisagni et al. · Annals of Oncology · 2018 · 155 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Oriana Nanni, D. Amadori, Andrea De Censi et al. · Breast Cancer Research and Treatment · 2018 · 108 citations · Full text

Medicine, Oncology, Pharmacology +15

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

Lucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni et al. · The Lancet Oncology · 2021 · 86 citations

Medicine, Oncology, Breast Oncology +14

Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study.

Laura Amaducci · PubMed · 1988 · 85 citations

Medicine, Neurology, Neuroscience +12